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Abstract
Objective: To be used in diagnostic studies, it must be demonstrated that biomarkers can differentiate between diseased 
and non-diseased patients. Therefore, the purpose of this study was to answer the following questions: (1) Is serum 
cartilage oligomeric matrix protein (sCOMP) elevated in patients with radiographically diagnosed knee osteoarthritis 
(OA) compared to controls? (2) Are there differences in sCOMP levels when comparing differing radiographic OA 
severities to controls? Methods: Systematic review and meta-analysis. Data Sources: A systematic search of CINAHL, 
PEDro, Medline, and SportsDiscus was completed in March 2010. Keywords: knee, osteoarthritis, sCOMP, radiography. 
Study inclusion criteria: Studies were written in English, compared healthy adults with knee OA patients, used the 
Kellgren Lawrence (K/L) classification, measured sCOMP, and reported means and standard deviations for sCOMP.
Results: For question 1, seven studies were included resulting in seven comparisons. A moderate overall effect size (ES) 
indicated sCOMP was consistently elevated in those with radiographically diagnosed knee OA when compared to 
controls (ES ¼ 0.60, P < 0.001). For question 2, four studies were included resulting in 13 comparisons between 
radiographic OA severity levels and controls. Strong ESs were calculated for K/L-1 (ES ¼ 1.43, P ¼ 0.28), K/L-3 (ES ¼ 
1.05, P ¼ 0.04), and K/L-4 (ES ¼ 1.40, P ¼ 0.003). A moderate ES was calculated for K/L-2 (ES ¼ 0.60, P ¼ 0.01).
Conclusions: These results indicate sCOMP is elevated in patients with knee OA and is sensitive to OA disease 
progression. Future research studies with a higher level of evidence should be conducted to investigate the use of this 
biomarker as an indicator for OA development and progression.
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Objective: To be used in diagnostic studies, it must be demonstrated that biomarkers can differentiate
between diseased and non-diseased patients. Therefore, the purpose of this study was to answer the
following questions: (1) Is serum cartilage oligomeric matrix protein (sCOMP) elevated in patients with
radiographically diagnosed knee osteoarthritis (OA) compared to controls? (2) Are there differences in
sCOMP levels when comparing differing radiographic OA severities to controls?
Methods: Systematic reviewandmeta-analysis.Data Sources: A systematic searchof CINAHL, PEDro,Medline,
and SportsDiscus was completed in March 2010. Keywords: knee, osteoarthritis, sCOMP, radiography. Study
inclusion criteria: Studies were written in English, compared healthy adults with knee OA patients, used the
Kellgren Lawrence (K/L) classification, measured sCOMP, and reported means and standard deviations for
sCOMP.
Results: Forquestion1, seven studieswere included resulting in sevencomparisons. Amoderate overall effect
size (ES) indicated sCOMPwas consistently elevated in thosewith radiographically diagnosed kneeOAwhen
compared to controls (ES ¼ 0.60, P < 0.001). For question 2, four studies were included resulting in 13
comparisons between radiographic OA severity levels and controls. Strong ESs were calculated for K/L-1
(ES ¼ 1.43, P ¼ 0.28), K/L-3 (ES ¼ 1.05, P ¼ 0.04), and K/L-4 (ES ¼ 1.40, P ¼ 0.003). A moderate ES was
calculated for K/L-2 (ES ¼ 0.60, P ¼ 0.01).
Conclusions: These results indicate sCOMP is elevated in patients with knee OA and is sensitive to OA
disease progression. Future research studies with a higher level of evidence should be conducted to
investigate the use of this biomarker as an indicator for OA development and progression.Introduction
Characterized by irreversible joint destruction such as cartilage
degradation, osteophyte development and joint space narrowing,
osteoarthritis (OA) affects millions of individuals each year1e4. Knee.M. Hoch, Division of Athletic
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Lattermann).OA, either affecting the patellofemoral or the tibiofemoral joint, is
the most common cause of disability in the United States2,5, causing
pain and loss of function1,3,6e8. Currently, there are few diagnostic
tools used to identify individuals with knee OA. The diagnosis of OA
is based on patient reports of pain and stiffness, and the presence of
osteophytes and joint space narrowing as viewed on radiographs.
Although many patients will demonstrate both symptomatic and
visual indicators of OA, there is not a direct correlation between
clinical indicators and actual joint damage2,9. Given the limitation of
current diagnostic tools and that early osteoarthritic changes such as
articular cartilage abnormalities are silent10, OA is often unrecog-
nized until it has reached an irremediable and disabling level2. The
ability to develop intervention strategies with the hope of delaying
irreversible joint damage remains difficult due to the lack of sensitive
and valid pre-radiographic diagnostic tools2. Identifications of
sensitive diagnostic tools to recognize pre-radiographic OA are
necessary in order to develop and implement intervention strategies
aimed at delaying irreversible joint damage2.
Several serum and/or synovial fluid biomarkers have been iden-
tified in the literature to diagnose pre-radiographic OA3,4,11e14. For
a biomarker to be useful in diagnosing early joint damage, it must be
sensitive to differences between healthy individuals and those with
OA, and also among varying degrees of severity of joint disease4,15,16.
Examples of these biomarkers include keratan sulfate12 and pento-
sidine11, bothwhich tend to be elevated in patients with OA. Another
biomarker that is theorized to have significant diagnostic value for
beginningOA, is serumcartilage oligomericmatrix protein (sCOMP)2.
Serum COMP is a non-collagen biomarker for cartilage degra-
dation present in articular cartilage, and other tissues such as
ligament, meniscus, synovial membrane, and tendon1,17e21.
Numerous studies have investigated the relationship of sCOMP in
patients with and without knee OA3,4,12,14,22,23. Validation of this
relationship will provide scientists and physicians with a prospec-
tive pre-radiographic diagnostic indicator that may be clinically
applicable and may assist in the development of treatment inter-
ventions for early stage OA.
The purpose of this systematic review was to answer the
following questions: (1) Is sCOMP elevated in patients with radio-
graphically diagnosed knee OA compared to controls? (2) Are there
differences in sCOMP levels when comparing differing radiographic
OA severities to controls?
Methods
Search strategy
A computerized literature searchwas completed inMarch of 2010
utilizing: CINAHL (from 1981), PEDro (from 1929) Medline (from
1966), and SportDiscus (from 1985). The search terms used were,
knee, osteoarthritis, sCOMP, and radiography. All abstracts from the
search results were reviewed. If the abstracts did not contain enough
information to include or exclude the study from the review, the
studywas reviewed in its entirety. In addition, all reference lists were
cross-referenced for relevant studies not included in the original
searches.
Criteria for study selection
The inclusion criteria for the studies used in this systematic
review were:
 Subjects with radiographically diagnosed knee OA and disease
free control groups.
 Studies using the Kellgren Lawrence (K/L) scale to classify knee
OA.
 Studies that measured sCOMP or used sCOMP as an outcome.
 Studies reportingmeans and associatedmeasures of variability.
 Studies using human adults (18þ years or older).
 Studies published in the English language.Assessment of publication bias
A funnel plot was used to provide an illustrative assessment of
publication bias. In addition, Duval and Tweedie’s Trim and Fill
method and Orwin’s Fail-Safe N were used to further interpret
possible publication bias. The Duvall and Tweedie’s Trim and Fill
method looks for missing studies on the left side of the mean effect
using a fixed effects model24. The asymmetric studies from the right
hand side of the mean effect are trimmed, the unbiased effect islocated, then the studies to left of the mean are then filled in24. This
method results in an adjusted cumulative effect, and provides
a conservative estimate of the total number of studies that are
“missing”. Orwin’s Fail-Safe N test was employed to assess the
robustness of the observed overall effects of the moderators on
sCOMP25.
Sensitivity analysis
The “one-study removedmethod”was used to test the stability of
the cumulative effect across the included studies by determining if
the results of one particular study substantially influenced the overall
effect24. The analysis systematically removes each study and replaces
it so that the influence of each study can be individually evaluated. If
the removal of any given study results in little change, it can be
concluded that the pooled result is robust24. For the second question,
we performed an additional sensitivity analysis to determine the
influenceof sample size on the overall effect for eachof the individual
K/L comparisons. Study comparisons were dichotomized into “large
(>10 subjects per group) or “small” (<10 subjects per group). As
a group, “large” studies and then “small” studies were selectively
removed in order to assess for changes in the overall result based on
sample size.
Assessment of study quality
The study quality was assessed independently by two authors
using a quality index for non-randomized studies26. This index was
adapted from a previously published version by Downs and Black27.
Based on the study designs for the included studies, the quality
index assessment tool26 was selected in order to compare case-
control and retrospective-cohort studies.
A total of 16 itemswereused to assess study quality for each study.
The quality index assessment tool addressed areas such as: clarity of
objectives, main outcomes, subject characteristics andmain findings,
as well as, external validity and internal validity concerning bias and
confounding26. Any discrepancies in scores between authors were
discussed and a mutual score was reached. Using previously pub-
lished criteria26, those studies achieving 75% of the criteria were
considered high quality, 60e74% were considered moderate quality,
and 60% were considered low quality.
Data extraction and statistical analysis
The variable of interest for this study was sCOMP. The reported
unit of measure is typically ng/ml, but sCOMP levels have been
reported using mg/ml and U/L. For meta-analysis, all sCOMP units of
measure were used for data extraction and statistical analysis.
Furthermore, in some cases sCOMP levels are not normally
distributed. Recognition of this will allow for the data to be
transformed using a logarithmic transformation, assuring the
assumptions of the general linear model23,28. For the purposes of
this meta-analysis, we recognize that a normal distribution might
not have been present before data analysis; however, we did not or
could not modify the data to control for this.
For this systematic review of the literature, K/L severity classi-
fication system for OA was used as an inclusion criterion. This
classification system was chosen as it is a common classification
system used to grade OA29. Studies using other forms of OA severity
classification systems were excluded to ensure consistent compar-
isons across all studies.
To determine if sCOMP was elevated in patients with radio-
graphically diagnosed kneeOAcompared to controls, bias-corrected
Hedges’s g30 effect sizes (ESs) were calculated to estimate differ-
ences between OA and control groups and 95% confidence intervals
(CI) to assess the uncertainty in these estimates. Hedge’s g adjusts
for sample size, which is often referred to as an unbiased estimate30.
When applicable, separate ESs were calculated for individual K/L
classifications compared to controls. All ESs, 95% CIs, and P-values
were calculated in Comprehensive Meta Analysis (Comprehensive
Meta Analysis Version 2.0, Biostat, Englewood, NJ). The calculated
Hedges’ g ES is a measure of a population’s mean effect estimated
under the assumption that the individual variability has a Gaussian
distribution. A positive ES indicated elevated sCOMP levels in OA
patients as compared to controls. ESs  0.40 were interpreted as
representing a weak effect, ESs between 0.41 and 0.69 were inter-
preted as representing a moderate effect, and ESs  0.70 were
interpreted as representing a strong effect31. An ES was interpreted
as statistically significant if <0.05 (in which the corresponding CI
would exclude the nil value).
Level of evidence
The level of evidence for the included studies was assessed using
the Oxford Centre for Evidence-Based Medicine (CEBM)-Levels of
Evidence32. The levels of evidence range from 1a to 5, with 1a rep-
resenting a systematic reviewof prospective cohort studies, and level
5 representing expert opinion without critical appraisal, bench
research or “first principles”. The CEBMstrength-of recommendation
grades are A, B, C, and D. Grade A represents consistent level 1
studies; grade B represents consistent level 2 or 3 studies or
extrapolations from level 1 studies; grade C represents level 4 studies
or extrapolations from level 2 or 3 studies; and grade D represents
level 5 evidence, troublingly consistent or inconclusive studies of any
level32.
Results
Study selection
Computerized and hand searches yielded 57 studies that were
included in the initial review (Fig. 1). Based on the inclusion criteriaFig. 1. Summary of search histand presentation of necessary data, a total of seven studies were
included in this review (Table I)3,4,11,12,14,23,33. The reason(s) for
exclusion for the remaining 50 studies can be found in the online
Appendix Table I.Is sCOMP elevated in patients with radiographic knee OA compared
to controls?
Seven studies met the inclusion criteria to answer this question
(Table I)3,4,11,12,14,23,33. The mean quality index assessment for the
included studies was 59% (25e87.5%). Three studies4,14,23 were
considered high quality, one3 was consideredmoderate quality, and
three studies11,12,33 were considered low quality. Level C evidence
exists that sCOMP is elevated in patients with knee OA. This
recommendation was reached based on consistent level 4 studies
with extrapolations from level 2 or 3 studies32.
A total of seven ESs and 95% CIs were calculated (Fig. 2).
Calculated ESs ranged from 0.06 [(CI) e 0.47e0.60] to 2.70
(1.85e3.54). A total of four ESs were weak, one ES was moderate
and two ESs were strong. The results of the random effects meta-
analysis revealed a moderate overall ES of 0.60 (0.25e0.94,
P ¼ 0.001), indicating sCOMP was consistently elevated in
patients with radiographically diagnosed knee OA compared to
controls.Publication bias
The trim and fill24 analysis indicated one study is missing, and
the addition of this study would result in an insignificant weak ES
of 0.39 (0.03e0.81, Fig. 3). In addition, the Orwin’s Fail-Safe N
indicated a range of 20e50 additional studies (based on the trivial
ES range of 0.05e0.10) would be needed to nullify the overall effect.
Therefore, the effect of publication bias introduced across the
studies is likely trivial. If all relevant studies beyond those analyzed
in this meta-analysis were included, the ES would probably remain
unchanged.ory and included studies.
Table I
Studies systematically reviewed to determine if sCOMP is elevated in patients with radiographically diagnosed knee OA
Authors Level of
evidence
(CEBM)
Quality index
score (%)
Study design OA group inclusion criteria No. control
patients
No. OA patients Dependent variables
measured
Cibere et al. (2009)14,* 2b 81.25% Exploratory
cohort
Aged 40e79 years; pain, aching,
or discomfort in or around the
knee on most days of the month
at any time in the past; any pain,
aching, or discomfort in or around
the knee in the past 12 months
16 Pre-ROA ¼ 105
ROA ¼ 80y
Total ¼ 185
C2C; C1, 2C; CPII; CS846;
NTX-I; CTX-II; HA; sCOMP;
WOMAC
Clark et al. (2007)4 2b 81.25% Retrospective
cohort
Caucasian, knee OA K/L  2 148 K/L 2 ¼ 109
K/L 3,4 ¼ 34
Total ¼ 143
sCOMP
Fernandes et al. (2007)3, z 4 68.75% Case control Aged 40e70 years, mechanical
pain in one or both knees for
minimum 3 months, and knee
crepitus upon clinical evaluation
86 SOA ¼ 75**
Pain ¼ 11
NOA ¼ 18**
Total ¼ 104
WOMAC; VAS and sCOMP
Jordan et al. (2003)23 2b 87.5% Retrospective
cohort
Radiographs and serum COMP
samples in database
302 K/L 2 ¼ 313
K/L 3 ¼ 110
K/L 4 ¼ 44
Total ¼ 467
sCOMP
Mundermann et al. (2009)33 4 43.75% Case control Definite osteophyte presence in
the medial or lateral tibiofemoral
compartment; a narrowest point
inter-bone distance of the medial
compartment less than the lateral
compartment; pain in and around
at least one knee for most of the
days in the past months; at least
some difficulty with two or more
items in the WOMAC physical
function scale
41 K/L 1 ¼ 11
K/L 2 ¼ 7
K/L 3 ¼ 12
K/L 4 ¼ 12
Total ¼ 42
Gait analysis; ambulatory
load and sCOMP
Senolt et al. (2004)11 4 25% Case control Undergoing arthrocentesis, no
history of renal disease of diabetes
mellitus and had normal levels
of creatinine
38 K/L 1 ¼ 2
K/L 2 ¼ 18
K/L 3 ¼ 14
K/L 4 ¼ 4
Total ¼ 38
sCOMP and Pentosidine
Wakitani et al.
(2007)12, yy
4 25% Case control Patients undergoing knee surgery 24 K/L 1 ¼ 7
K/L 2 ¼ 4
K/L 3 ¼ 6
K/L 4 ¼ 7
Total ¼ 24
Articular cartilage assessment,
keratan sulfate, CS6, CS846,
HA and sCOMP and synovial
COMP
* Pre-ROA ¼ pre-radiographic OA (K/L < 2); ROA ¼ radiographic OA (K/L  2); C2C ¼ Type II collagen cleavage neopeptide; C1, 2C ¼ Types I and II collagen cleavage neoepitope; CS846 ¼ cartilage proteoglycan aggrecan
turnover epitope; NTX-I ¼ N-telopeptide of type I collagen; CTX-II ¼ C-telopeptide of type II collagen; HA ¼ hyaluronan acid; WOMAC ¼ Western Ontario McMaster University Index.
y Only the ROA group was used for this review.
z SOA (symptomatic OA) ¼ K/L grades 2, 3, 4; NOA (non-symptomatic OA) ¼ K/L 2 or higher; Pain ¼ K/L 0 or 1; VAS ¼ visual analog scale.
** Only the SOA and NOA groups were used for this review.
yy C6S ¼ chondroitin 6 sulfate.
Hedges's Lower Upper 
g limit limit p-Value
Cibere et al. (2009) Control vs. K/L 2,3,4 0.061 -0.472 0.593 0.822
Clark et al. (1999) Control vs. K/L 2,3,4 0.304 0.074 0.535 0.010
Fernandes et al. (2007) Control vs. K/L 2,3,4 1.075 0.492 1.658 0.000
Jordan et al. (2003) Control vs. K/L 2,3,4 0.375 0.229 0.520 0.000
Mundermann et al. (2009) Control vs. K/L  1,2,3,4 0.061 -0.365 0.488 0.778
Senolt et al. (2004) Controls vs. K/L 1,2,3,4 0.586 0.131 1.041 0.012
Wakitani et al. (2007) Controls vs. K/L 1,2,3,4 2.697 1.853 3.541 0.000
0.600 0.253 0.947 0.001
-4.00 -2.00 0.00 2.00 4.00
14
4
3
33
11
23
12
sCOMP lower sCOMP higher
Fig. 2. A Forest plot depicting the calculated ESs of sCOMP in patients with radiographically diagnosed knee OA when compared to controls. The diamond at the bottom of the plot
represents the overall ES.Sensitivity analysis
Following the one-study removed method, the ESs ranged from
0.37 to 0.71. The lowest lower confidence limit was 0.17 and the
highest upper confidence limit was 1.20. All P-values were P < 0.01.
This indicated that there was not one particular study which
substantially influenced the overall effect.Are there differences in sCOMP levels when comparing differing
radiographic OA severities to controls?
To be included in data analysis, a study must have presented data
for theK/L severities in order tomake control comparisons. Using this
additional inclusion criteria, four studies4,11,12,23 were included and
13 comparisons were made (Table I). The mean quality index
assessment for the included studies used to answer this questionwas
56% (25e87.5%). Two studies4,23 were considered high quality and
two studies11,12 were considered low quality. Level C evidence exists
that sCOMP levels are elevated according to OA severity when
compared to healthy controls. This recommendation was reached
basedon consistent level 4 studieswithextrapolations from level 2 or
3 studies32.
A total of 13 comparisons were used, with a calculated overall
effect of 1.00 (0.65e1.35, P < 0.001). To answer question 2, subgroup
ESs were calculated for each of the OA severities (K/L-1,-2, etc.)-3 -2 -1 0 1 2 3
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Fig. 3. A funnel plot of standard error by Hedges’s g using Duval and Tweedie’s Trim and
Fillmethod to assess publication bias of the studies used to determine if sCOMP is elevated
in patients with radiographically diagnosed knee OA when compared to controls.compared to controls. Strong ESs were observed for K/L-1, K/L-3, and
K/L-4 while a moderate ES was observed for K/L-2 (Fig. 4). The
subgroup ES for the K/L-1 comparison11,12 was 1.43 (1.15e4.02,
P¼ 0.28). The subgroup ES for the K/L-2 comparison4,11,12,23 was 0.60
(0.13e1.06, P ¼ 0.01). The subgroup ES for the K/L-3 compar-
ison11,12,23 was 1.05 (0.06e2.03, P ¼ 0.04). The subgroup ES for the
K/L-4 comparison4,11,12,23 was 1.40 (0.47e2.36, P ¼ 0.003)4,11,12,23.
Our results indicate a significant moderate effect for K/L-2, and
a significant strong effect for K/L-3 and K/L-4 when compared to
controls. Therefore, the subgroup meta-analysis revealed strong
trends in elevated sCOMP levels as OA severity levels increase.
However, the CIs for the ESs of each subgroup do overlap, therefore
caution must be used when interpreting these results.
Publication bias
A publication bias assessment using the trim and fill method24
was performed for all 13 comparisons. The results indicated publi-
cation bias is likely and there are five comparisons missing (Fig. 5).
The addition of these five comparisons to the left of the overall mean
effect would result in an insignificant weak overall effect of 0.39
(0.002e0.79), with the CIs crossing zero. Additionally, the results of
Orwin’s Fail-Safe N indicated a range of 44e100 additional studies
(based on the trivial ES range of 0.05e0.10) would be needed to
nullify the overall effect. Therefore, the effect of publication bias
introduced across the studies is trivial. If all relevant studies beyond
those analyzed in this meta-analysis were included, the ES would
probably remain unchanged.
Sensitivity analysis
Following the one-study removed method; the ESs remained
strong and ranged from 0.78 to 1.30. The lowest lower confidence
limit was 0.48, and the highest upper confidence limit was 1.60. All
P-values were P < 0.001. This indicated that there was not one
particular comparison that substantially influenced the overall
effect calculated for the question.
A sense of cautionmust be employedwhen interpreting the K/L-1
vs control ES, as the two comparisons used to calculate this ES had
a combined total of nine subjects in the group, and the CI encom-
passed zero. Given the recent results of a meta-epidemiological
study34, small comparisons such as those exhibited in the K/L-1
comparison, can inflate the overall effect (see K/L-1 diamond,
Fig. 4). In order to determine the effect of the smaller subgroups
(n < 10) on the overall ESs, we performed a sensitivity analysis
comparing the overall effect of large vs small subgroups. The results
of this analysis (Fig. 6) indicated small groups had a much larger
overall effect (ES ¼ 2.33, CI: 1.09e3.60), compared to larger groups
Group by
Subgroup within study
Study name Subgroup within study Statistics for each study Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-Value
Control vs. K/L 1 Senolt et al. Control vs. K/L 1 0.070 -1.323 1.464 0.921
Control vs. K/L 1 Wakitani Control vs. K/L 1 2.708 1.646 3.769 0.000
Control vs. K/L 1 1.429 -1.154 4.012 0.278
Control vs. K/L 2 Clark et al. Control vs. K/L 2 0.255 0.007 0.503 0.044
Control vs. K/L 2 Jordan et al. Control vs. K/L 2 0.275 0.116 0.433 0.001
Control vs. K/L 2 Senolt et al. Control vs. K/L 2 0.476 -0.084 1.036 0.096
Control vs. K/L 2 Wakitani Control vs. K/L 2 3.410 2.049 4.772 0.000
Control vs. K/L 2 0.597 0.127 1.066 0.013
Control vs. K/L 3 Jordan et al. Control vs. K/L 3 0.274 0.056 0.493 0.014
Control vs. K/L 3 Senolt et al. Control vs. K/L 3 0.828 0.204 1.453 0.009
Control vs. K/L 3 Wakitani Control vs. K/L 3 2.426 1.360 3.491 0.000
Control vs. K/L 3 1.045 0.061 2.030 0.037
Control vs. K/L 4 Clark et al. Control vs. K/L 4 0.492 0.118 0.867 0.010
Control vs. K/L 4 Jordan et al. Control vs. K/L 4 0.777 0.456 1.098 0.000
Control vs. K/L 4 Senolt et al. Control vs. K/L 4 0.785 -0.239 1.810 0.133
Control vs. K/L 4 Wakitani Control vs. K/L 4 4.723 3.290 6.156 0.000
Control vs. K/L 4 1.398 0.472 2.325 0.003
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Fig. 4. A Forest plot depicting the calculated ESs of sCOMP exist when comparing patients with differing radiographic knee OA severities compared to controls. Each of the
diamonds represents the overall ES for each of the comparisons made for each (K/L) classification.(ES ¼ 0.41, CI: 0.25e0.60), demonstrating small groups significantly
influenced the overall effect for each subgroup. However, if we were
to remove the comparisons with <10 subjects per group, no
comparisons would be available for the K/L-1 severity.
Discussion
To be a useful biomarker for the diagnosis of pre-radiographic
knee OA, the biomarker must have a strong correlation with the
disease, thereby having levels that are distinguishable between
patients with andwithout the condition4,15,16. Based on the results of
this systematic review, we concluded that sCOMP is consistently
elevated in patients with radiographic knee OA compared to healthy
controls (Fig. 2). Furthermore, higher levels of sCOMP are associated
with a trend toward greater radiographic OA severity when
compared to controls, as indicated by the ESs (Fig. 3). Further-5 -4 -3 -2 -1 0 1 2 3 4 5
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Fig. 5. A funnel plot of standard error by Hedges’s g using Duval and Tweedie’s Trim
and Fill method to assess publication bias of the comparisons used to determine if
differences in sCOMP levels exist when comparing differing knee OA severities when
compared to healthy controls.investigation is warranted to determine if this marker can be utilized
to assess the presence of pre-radiographic OA, and in evaluating OA
interventions in order to delay permanent joint degradation.
Study quality assessment
The mean quality index assessment for these studies was 59%.
Three4,14,23 of the studies were considered high quality, one was
considered moderate quality3 and three of the studies11,12,33 were
considered low quality. For the studies that were considered low
quality, a majority of the criteria examining external and internal
bias were either unable to be determined or not represented in the
manuscript. These criteria included subject recruitment and repre-
sentation of the population being sampled, blinding of investigators,
appropriateness of statistical tests used and validity and reliability of
the measurement tools used. Also, missing were criteria that were
specific to internal validity. For example, a majority of the internal
validity (confounding) criteria were not represented in most
manuscripts considered moderate and low quality. These criteria
addressed whether subjects were recruited from the same pop-
ulation, during the same period of time and if there was adequate
adjustment for confounding in the analyses.
K/L classification and assessment
As part of the inclusion criteria, the K/L classification for knee OA
must have been included and reported. This classification system
was chosen because it is the most commonly used radiological
classification system used to grade OA29. Two studies reviewed did
not report the number of radiologists used to determine K/L clas-
sification12,33. Senolt et al.11 reported the use of two radiologists for
the review of subject radiographs and K/L classification assignment.
One of the studies reported using a blinded rheumatologist to
assign K/L classifications3. Cibere et al.14 reported two blinded
investigators with good interrater reliability (ICC ¼ 0.79) read the
radiographs and independently classified the patients. Consensus
was reached between readers if they disagreed on K/L classification
for the patients14. Finally, two studies reported the use of a single
radiologist assessing the radiographs for K/L classification
Group by
Subgroup within study
Study nameSubgroup within study Statistics for each study Hedges's g and 95%  CI
Hedges's Lower Upper 
g limit limit p-Value
large Clark et al 2 large 0.255 0.007 0.503 0.044
large Clark et al.4 large 0.492 0.118 0.867 0.010
large Jordan et al.2large 0.275 0.116 0.433 0.001
large Jordan et al.3large 0.274 0.056 0.493 0.014
large Jordan et al.4large 0.777 0.456 1.098 0.000
large Senolt et al.2 large 0.476 -0.084 1.036 0.096
large Senolt et al.3 large 0.828 0.204 1.453 0.009
large 0.408 0.251 0.566 0.000
small Senolt et al.1 small 0.070 -1.323 1.464 0.921
small Senolt et al.4 small 0.785 -0.239 1.810 0.133
small Wakitani 1 small 2.708 1.646 3.769 0.000
small Wakitani 2 small 2.426 1.360 3.491 0.000
small Wakitani 3 small 4.723 3.290 6.156 0.000
small Wakitani 4 small 3.410 2.049 4.772 0.000
small 2.332 1.087 3.577 0.000
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Fig. 6. A Forest plot depicting the calculated ESs for large groups (n > 10) and small groups (n < 10) used to answer the second question.assignment and reported the inter- and intrarater reliability4,23. It is
important to report the number of individuals that are involved in
reviewing radiographs, as this informationwill allow the readers to
understand that bias was adequately controlled for. Also, reporting
the inter- and intrarater reliability allows for interpretation of the
generalizability of these measures among different clinicians.
Only three studies used in this review provided definitions for
each of the K/L classifications used to assessOA severity3,4,23. A recent
review of K/L classifications used in current published research,
specifically in reference to a grade of 2, reported grade 2 definitions
are different throughout the reported literature29. Therefore it is
essential the K/L grades be defined in each of the studies35. Knowing
which definition the authors used to identify K/L-2 subjects will
allow better comparisons to be made across the studies.
Serum COMP ELISAs and associated coefficients of variation (CV)
It has been previously reported that certain ELISAs are more
appropriate for detecting human sCOMP than others36. For the
purposes of this systematic review we did not exclude studies based
on the ELISA used to detect human sCOMP levels. Therefore,multiple
ELISAs were used to detect human sCOMP for the studies that were
included in our review (Table II). Three studies used an ELISATable II
ELISA manufacture information and associated CVs for each of the studies
Study ELISA manufacture information Type of ELISA Spe
Cibere et al.14 AnaMar Medical,
Lund, Sweden
Sandwich Two
(not
Clark et al.4 In house method* Competitive Mon
Fernandes et al.3 Anamar Medical,
Uppsala, Sweden
Sandwich Two
(not
Jordan et al.23 In house method* Sandwich Mon
and
Mundermann et al.33 AnaMar Medical AB,
Lund, Sweden
Sandwich Mou
(not
Senolt et al.11 In house method* Sandwich Mon
17-C
Wakitani et al.12 Kamiya Biomedical Company,
Seattle, WA.
Sandwich Not
* The same in house method was used for each of these studies, and the informatio
Tchetverikoc I, Kraus VB, et al. Monoclonal antibodies to human cartilage oligomeric mat
2003;328:59e69. However, it must be noted that Clark et al.4 and Jordan et al.23 reportemanufacturedbyAnaMarMedical3,14,33, three studies4,11,23 used an in
house ELISA as previously reported by Vilim et al.37, and one study
used an ELISA manufactured by Kamiya Biomedical Company12. The
study using the Kamiya Biomedical Company ELISA12 did have the
largest calculated ES. However, the authors cannot concludewhether
or not this ELISA was more sensitive than the others used in this
review. Itmust be noted that Jordan et al.23 and Clark et al.4 did report
modifications to the Vilim et al.37 ELISA protocol in that an alkaline
phosphatase-conjugated avidin was used rather than the previously
reported peroxidase.
Previous research reported a weak correlation (R2 ¼ 0.210)
between the AnaMar Medical ELISA and the in house ELISA reported
by Vilim et al.36,37 for measuring sCOMP levels in the same
subjects36. For the purposes of this review, readers must be aware
that there are differences in detecting sCOMP levels for each of the
different ELISAmanufactures. The only way to ascertainwhich ELISA
kit is the best at detecting sCOMP levels can only be accomplished by
comparing each technique with serum samples from the same
subjects, which cannot be done using the available data for this
meta-analysis. One advantage of the data contained within this
systematic review and meta-analysis is that the ESs provide a unit-
less measure of the magnitude of change between groups which
allow standardization for comparison between studies.cific antibodies used Interassay CV Intraassay CV
monoclonal antibodies
specified)
<5% <5%
oclonal antibody 17-C10 Not reported Not reported
monoclonal antibodies
specified)
Not reported Not reported
oclonal antibodies 16-F12
17-C10
9.7% for “normal”
controls 8.7% for
“high” controls
5.8% for “normal” controls
6.6% for “high” controls
se monoclonal antibodies
specified)
<1.9% <2.7%
oclonal antibodies
10 and 16-F12
Not reported Not reported
specified Not reported Not reported
n regarding this method can be found in Vilim V, Voburka Z, Vytasek R, Senolt L,
rix protein: epitope mapping and characterization of sandwich ELISA. Clin Chim Acta
d slight modifications to the in house method used for their studies.
CVs are reported in order to determine the assay variability, and
the interassay and intraassay CVs are most commonly reported38.
Four studies did not report the inter- or intraassay CVs for the ELISAs
used to determine human sCOMP3,4,11,12. Three studies did report
inter- and intraassay CVs; with Mundermann et al.33 reporting the
lowest CVs (<1.9% for interassay, <2.7% for intraassay). Table II
reports the inter- and intraassay CVs for each of the studies used
in this systematic review and meta-analysis. The acceptable range of
reportable CVs are often laboratory specific, therefore it is important
that this information be presented in order to ascertain the vari-
ability of the reported sCOMP levels in each of the ELISAs performed.
Sensitivity analysis and publication bias assessments
We conducted two separate sensitivity analyses. For the first
question, the lowest pooled ES was interpreted as weak (ES ¼ 0.37,
CI: 0.18e0.60). For the second analysis, the lowest pooled ES was
interpreted as strong (ES ¼ 0.78, CI: 0.50e1.01). Based on these
findings, we concluded that our reported results were stable, and
that no individual study substantially influenced the overall pooled
effects calculated for either meta-analysis.
For the second question, we performed a sensitivity analysis
investigating the effects of the small groups (n < 10) on the overall
effects for each of the subgroups (Fig. 6). The results of this sensi-
tivity analysis revealed the small groups have a much larger overall
effect (ES ¼ 2.33, CI: 1.1e3.6) compared to the large groups
(ES ¼ 0.41, CI: 0.25e0.60). However, the smaller groups also
demonstrated greater imprecision, indicating potentially inflated
results of the smaller groups which will directly influence the
overall effect.
We also assessed publication bias using the Orwin’s Fail-Safe
N25 and Duval and Tweedie’s Trim and Fill method24. Although
the initial funnel plot indicated there was a possibility of publica-
tion bias for each of our questions (Figs. 3 and 5), our secondary
publication bias analysis indicated thatmore than 20 studies for the
first question and 44 studies for the second question, with non-
significant results, would need to be included in the analysis in
order to make the pooled results become trivial and nullify our
overall effects.
Limitations
This review is not without limitations. First, it must be noted
that only studies using the K/L classification scale for OA were
included. This classification system was chosen as it is a common
classification system used to grade OA29. There are other systems
for classifying OA; however, we chose to use only the K/L classifi-
cation scale in order to ensure consistent comparisons across
studies.
Second, a recent meta-epidemiological study associated with
randomized control trials for OA treatment determined smaller
studies (n< 100) can have a deleterious effect on the interpretation
of the overall meta-analysis results34. For the purposes of our meta-
analysis, we considered a group small if they contained <10
subjects. For question 2, we had six groups that were considered
small. In order to determine whether or not these groups had
a harmful effect on the overall ESs for each subgroup, we conducted
a secondary analysis of small vs large comparisons (Fig. 6). Based on
this analysis, we determined that the small group comparisonsmay
inflate the overall ESs. Therefore caution is necessary when inter-
preting our results for the K/L-1 comparison as this subgroup only
had nine subjects. In addition, it was not possible to determine if
several of the studies were prospective or retrospective in nature.
Inclusion of this information in the future will allow more accurate
synthesis of the available data.Conclusions
The usefulness of sCOMP as a diagnostic biomarker for identifi-
cation of knee OA prior to the occurrence of permanent joint degra-
dation is contingent upon the sensitivity to detect differences in
patients with and without the disease and between differing sever-
ities of the disease4,15,16. For both questions posed in this review, level
C evidence is currently available in the literature. This recommen-
dation was reached based on consistent level 4 studies or extrapo-
lations from level 2 studies32. To strengthen this recommendation,
future rigorous prospective investigations should be conducted.
However, based on the available reported data, our results indicate
sCOMP is elevated in patients with diagnosed knee OA compared to
controls (Fig. 2). Furthermore, clear trends were identified based on
disease severity with larger ESs for K/L-3 and K/L-4 comparisons
when compared to K/L-2 comparisons (Fig. 4).
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